Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Carcinoma, Squamous Cell
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cells, Cultured
Cisplatin
/ pharmacology
Drug Synergism
Humans
Mouth Neoplasms
/ metabolism
Plasma Gases
/ pharmacology
Reactive Oxygen Species
/ metabolism
cisplatin
cold atmospheric plasma
combination therapy
reactive oxygen species
squamous cell carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Oct 2020
15 Oct 2020
Historique:
received:
06
09
2020
revised:
12
10
2020
accepted:
13
10
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Cold atmospheric plasma (CAP) has been extensively investigated in the local treatment of cancer due to its potential of reactive oxygen species (ROS) generation in biological systems. In this study, we examined the synergistic effect of combination of CAP and cisplatin-mediated chemotherapy of oral squamous cell carcinoma (OSCC) in vitro. SCC-15 OSCC cells and human gingival fibroblasts (HGF-1) cells were treated with cisplatin, and then, the cells were irradiated with CAP. Following this, viability and apoptosis behavior of the cells were investigated. The viability of SCC-15 cells was inhibited by cisplatin with a dose-dependent manner and CAP treatment time. HGF-1 cells also showed decreased viability by treatment with cisplatin and CAP. Combination of 1 μM cisplatin plus 3 min of CAP treatment or 3 μM cisplatin plus 1 min of CAP treatment showed a synergistic anticancer effect with appropriate cytotoxicity against normal cells. ROS generation and dead cell staining were also increased by the increase in CAP treatment time. Furthermore, tumor-suppressor proteins and apoptosis-related enzymes also increased according to the treatment time of CAP. We showed the synergistic effect of cisplatin and CAP treatment against SCC-15 cells with low cytotoxicity against normal cells.
Identifiants
pubmed: 33076565
pii: ijms21207646
doi: 10.3390/ijms21207646
pmc: PMC7588898
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Plasma Gases
0
Reactive Oxygen Species
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Free Radic Biol Med. 2018 Dec;129:537-547
pubmed: 30355525
Oxid Med Cell Longev. 2017;2017:1289041
pubmed: 28694913
Oncotarget. 2018 Apr 6;9(26):18002-18017
pubmed: 29719586
Biomed Res Int. 2018 Mar 19;2018:7364539
pubmed: 29750170
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
PLoS One. 2014 Jan 21;9(1):e86173
pubmed: 24465942
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007464
pubmed: 22696370
Free Radic Biol Med. 2017 Sep;110:280-290
pubmed: 28666851
Arch Biochem Biophys. 2016 Sep 1;605:102-8
pubmed: 26820218
Sci Rep. 2016 Jul 01;6:29098
pubmed: 27364563
Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907
pubmed: 28730291
Int J Nanomedicine. 2013;8:2835-45
pubmed: 23966778
Int J Mol Sci. 2017 Feb 10;18(2):
pubmed: 28208642
Expert Rev Med Devices. 2013 May;10(3):367-77
pubmed: 23668708
J Natl Compr Canc Netw. 2006 Oct;4(9):941-6
pubmed: 17020670
Mutat Res Genet Toxicol Environ Mutagen. 2016 Mar;798-799:48-54
pubmed: 26994493
Biointerphases. 2015 Jun 19;10(2):029403
pubmed: 25791295
J Wound Care. 2018 Sep 1;27(Sup9):S4-S10
pubmed: 30207843
Sci Rep. 2019 Mar 11;9(1):4099
pubmed: 30858524
J Clin Med. 2019 Nov 09;8(11):
pubmed: 31717600
Oxid Med Cell Longev. 2019 Sep 3;2019:3873928
pubmed: 31565150
Sci Rep. 2018 May 16;8(1):7689
pubmed: 29769707
Phys Chem Chem Phys. 2018 Apr 4;20(14):9198-9210
pubmed: 29560996
BMC Cancer. 2012 Oct 15;12:473
pubmed: 23066891
Cancer Chemother Pharmacol. 2016 Jun;77(6):1103-24
pubmed: 26886018
Chin Clin Oncol. 2017 Oct;6(5):49
pubmed: 29129089
Pathol Int. 2018 Jan;68(1):23-30
pubmed: 29235204
Anticancer Agents Med Chem. 2018;18(6):769-775
pubmed: 28762318
J Indian Soc Periodontol. 2011 Oct;15(4):304-9
pubmed: 22368351
Cancer Treat Rev. 2003 Oct;29(5):371-87
pubmed: 12972356
J Pediatr Hematol Oncol. 2019 Mar;41(2):e97-e100
pubmed: 30095690
Arch Med Sci. 2015 Dec 10;11(6):1286-95
pubmed: 26788092
Clin Oral Implants Res. 2020 May;31(5):442-451
pubmed: 31957070
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708225
Cochrane Database Syst Rev. 2017 Jun 23;6:CD003374
pubmed: 28643430
Cancer Res. 2003 Dec 15;63(24):8977-83
pubmed: 14695216
Jpn J Clin Oncol. 2016 Jan;46(1):4-12
pubmed: 26486825
Anticancer Agents Med Chem. 2018;18(6):768
pubmed: 30468121
PeerJ. 2017 Aug 25;5:e3751
pubmed: 28852598
Expert Opin Emerg Drugs. 2015 Jun;20(2):165-82
pubmed: 25578210
Biol Chem. 2018 Dec 19;400(1):39-62
pubmed: 30044757
Biomedicines. 2017 Jul 01;5(3):
pubmed: 28671579
World J Urol. 2019 Sep;37(9):1759-1765
pubmed: 30392011
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9445-9453
pubmed: 31773682
PLoS One. 2019 Apr 9;14(4):e0215099
pubmed: 30964925
J Int Acad Periodontol. 2015 Jul;17(3):82-90
pubmed: 26373225
Sci Rep. 2018 Aug 15;8(1):12214
pubmed: 30111887